早期乳腺癌延长内分泌治疗的研究进展  

Progress of extended adjuvant endocrine therapy for early-stage breast cancer

作　　者：周易 刘晓安[1] ZHOU Yi;LIU Xiaoan(Department of Breast Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China)

机构地区：[1]南京医科大学第一附属医院乳腺外科,江苏南京210029

出　　处：《中国肿瘤外科杂志》2022年第2期200-204,共5页Chinese Journal of Surgical Oncology

摘　　要：乳腺癌是常见的女性恶性肿瘤。大多数激素受体阳性乳腺癌能够早期诊断并使用辅助内分泌治疗,但乳腺癌复发的风险在5年辅助内分泌治疗后持续存在,且具有累积性。为了减轻这些风险,既往研究已经评估了延长内分泌治疗的使用。文章选择内分泌治疗方案和延长内分泌治疗的相关数据,总结延长内分泌治疗的意义及可能从中受益的患者、当前内分泌治疗可能出现的不良反应。延长他莫昔芬治疗可使患者得到总生存获益,而延长芳香化酶抑制剂的使用则显示适度的无病生存率获益。在选择延长内分泌治疗时应综合考虑个体患者延长内分泌治疗的可能获益和患者自身的耐受性。Breast cancer is the most commonly diagnosed cancer in the world.While most hormone receptor-positive breast cancers can be diagnosed at the early stage and treated with adjuvant endocrine therapy.However,the risk of breast cancer recurrence persists despite current therapeutic approaches.Previous clinical trials have evaluated the practice of extended endocrine therapy aiming at reducing the risk.This article provides an overview of the effectiveness of extended endocrine therapy and the possible side effects of current endocrine therapy.In general,overall survival benefit has been demonstrated with extended tamoxifen treatment,whereas the use of extended aromatase inhibitors has shown modest disease-free survival benefit.Therapeutic approaches for individual patients should depend on the possible benefit and tolerability of extended endocrine therapy.

关 键 词：乳腺癌 辅助内分泌治疗 延长内分泌治疗 他莫昔芬 芳香化酶抑制剂 

分 类 号：R73[医药卫生—肿瘤]